We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging AxoGen (AXGN) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has AxoGen (AXGN - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
AxoGen is a member of the Medical sector. This group includes 974 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. AxoGen is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for AXGN's full-year earnings has moved 27.1% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, AXGN has moved about 1.9% on a year-to-date basis. Meanwhile, stocks in the Medical group have lost about 0.7% on average. As we can see, AxoGen is performing better than its sector in the calendar year.
Arcutis Biotherapeutics, Inc. (ARQT - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 27%.
Over the past three months, Arcutis Biotherapeutics, Inc.'s consensus EPS estimate for the current year has increased 20.9%. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, AxoGen belongs to the Medical - Instruments industry, a group that includes 83 individual companies and currently sits at #94 in the Zacks Industry Rank. On average, this group has lost an average of 9.1% so far this year, meaning that AXGN is performing better in terms of year-to-date returns.
Arcutis Biotherapeutics, Inc., however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 485-stock industry is ranked #97. The industry has moved +5.6% so far this year.
Going forward, investors interested in Medical stocks should continue to pay close attention to AxoGen and Arcutis Biotherapeutics, Inc. as they could maintain their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging AxoGen (AXGN) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has AxoGen (AXGN - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
AxoGen is a member of the Medical sector. This group includes 974 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. AxoGen is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for AXGN's full-year earnings has moved 27.1% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, AXGN has moved about 1.9% on a year-to-date basis. Meanwhile, stocks in the Medical group have lost about 0.7% on average. As we can see, AxoGen is performing better than its sector in the calendar year.
Arcutis Biotherapeutics, Inc. (ARQT - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 27%.
Over the past three months, Arcutis Biotherapeutics, Inc.'s consensus EPS estimate for the current year has increased 20.9%. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, AxoGen belongs to the Medical - Instruments industry, a group that includes 83 individual companies and currently sits at #94 in the Zacks Industry Rank. On average, this group has lost an average of 9.1% so far this year, meaning that AXGN is performing better in terms of year-to-date returns.
Arcutis Biotherapeutics, Inc., however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 485-stock industry is ranked #97. The industry has moved +5.6% so far this year.
Going forward, investors interested in Medical stocks should continue to pay close attention to AxoGen and Arcutis Biotherapeutics, Inc. as they could maintain their solid performance.